Avadel pharmaceuticals to provide a corporate update and report second quarter 2021 financial results on august 9th

Dublin, ireland, aug. 02, 2021 (globe newswire) -- avadel pharmaceuticals plc (nasdaq: avdl), a company primarily focused on developing ft218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness (eds) and cataplexy in adults with narcolepsy, announced today that it will host a conference call and live webcast at 8:30 a.m. et on monday, august 9, 2021, to provide a corporate update and discuss the company's financial results for the second quarter ended june 30, 2021.
AVDL Ratings Summary
AVDL Quant Ranking